Chemotherapy

The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, exp~sion has been rapid, for example in cephalosporins, pen­ icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es­ pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is rece1v1ng increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu­ losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur­ rent progress in chemotherapy.

Contenu

On the Cytogenetic Criteria of Rational Tumor Chemotherapy.- Life Prolongation of Mice Bearing Syngeneic Tumor, Leukemia P388 with the Streptococcal Preparation, OK-432 and Its Mechanism of Action.- Breakdown of Non-Immune Metastasis Resistance after Cytostatic Drugs.- Prevention of Lymphoma Growth in Mice by a Covalent Drug-Carrier-Antibody Complex.- Effects of Anti-DNA and Anti-RNA Antibodies Bound to Melphalan and Methotrexate on C3H Mammary Adenocarcinoma and L1210 Leukaemia.- Immunosuppressive Effects of Some Organic Compounds with Anti-Inflammatory Activity.- Differential Immunosuppressive Effects of Anticancer Agents on Lymphoid Subpopulations.- Experiments and Theoretical Considerations on Synchronisation of L1210 Ascites Tumour Cells and Crypt Epithelia of the Mouse with Vincristine.- Theoretical Bases for Designing Combination Therapy with Dibromodulcitol (DBD).- Tilorone HYdrochloride: Its Pharmacokinetic Parameters and Its Pharmacodynamic Effects.- Pharmacokinetics of Futraful (FT-207) for Clinical Application.- Effects of Cytotoxic Drugs and/or Corticosteroids on Peripheral Leukocytes.- The Effectiveness of Sequential Therapy Schedules with Adriamycin and Cyclophosphamide in the P388 Leukemia Model.- Antitumor Activity of Mimosine and Mimosine HYdrochloride Against B16 Melanoma in BDF1 Mice.- A New Multipeptide Antitumour Drug.- Metabolism of the Tumour-Inhibitory 3,3-Dimethyl-1-Phenyl-Triazene and Its 4-Chlorophenyl Analogue.- Antitumour Activity of Benzofuroxan Derivatives.- Antitumour Activity of Tetrazolopyridazines and Tetrazolophthalazines.- Antineoplastic Effect of Compound 9777-VUFB in Animals with Experimental Tumours; Its Interaction with Some Cutostatics.- Effects of GP 48 989 Alone and in Combination with Hormones and Chemotherapeutic Agents on DMBA-Induced Mammary Carcinomata II.- R 17934: A New Synthetic Anticancer Drug Interfering with Microtubules.- Antitumour Activity of Carminomycin.- Variamycin, a New Antitumour Antibiotic.- Inhibition by Caffeine of Post-Replication DNA Repair in Hamster Cells Treated with cis platinum (II) Diammine Dichloride.- The Role of Nuclear Proteins in the Chemotherapeutic Effect of Dibromodulcitol (DBD).- The Effect of Dibromodulcitol on the Replication of DNA in Yoshida Sarcoma Cells.- Clinical Cancer Chemotherapy with Drugs Aimed at Gene Regulators.- Characterization of the Bleomycin Action on DNA.- Antitumour Antibiotic Carminomycin: Mechanism of Action.- Effect of Combined Chemotherapy with Lysosome Labilizers and Mitomycin-C.- Optimal Conditions for Tumor Chemotherapy Chosen on the Basis of Changes in the Lipid Antioxidant Activity.- An Antitemplate Approach to Develop Selective Inhibitors of Oncornaviral Reverse-Transcriptase.- Experimental Approach to Increase the Effects of Cancer Chemotherapy in Tumor-Bearing Rats Pretreated with an Inducer on Microsomal Drug-Metabolizing Enzyme (cytochrome p-450).- Effect of the Drug-Metabolizing Enzyme Inducers on the Cytostatic Activity of Dibromodulcitol.- Studies of N-Methyl-N-Nitrosourea-C14O Pharmacokinetics in Mice with Hepatoma 22A.- Collateral Sensitivity Between an Alkylating Agent and Halogenated Methotrexate.- Meso-1,2 bis-(3,5-Dioxopiperazine-1-y1)-1,2-Dimethyl-ethane (ICRF 193): A Potent Antitumour Analogue of ICRF 159.- New Derivatives of Nitrosourea with a High Therapeutic Index for Oncostatism and Immunosuppression.- Effect on L1210 Leukaemia, on Antibody Forming Cells, and on Macrophage cytotoxicity of Ellipticine and Three Derivatives.- Antitumor Activity of Daunorubicin Derivatives.- New Antitumour Analogues of Cytosine Arabinoside and the Effect Against Mouse Leukemia L1210.- Exceptional Responses to Chemotherapy and/or Hormonotherapy of Cases with Generalized Cancer.- Clinical Considerations in Myelomatosis.- Chronic Gastritis, Atypical Epithelia in Biopsies and Therapeutic Consequences.- Clinical Studies on Changes in Serum Glycoproteins in Cancer Chemotherapy.- Double-Blind Trial with Levamisole in Resectable Lung Cancer.- Carcino-Embryonic Antigen Determinations and Chemotherapy in Cancer Patients.- Aspects of Chemo-Immunotherapy in a Controlled Clinical Study for the Treatment of Bronchogenic Cancer.- Pulse-Cytophotometric Monitoring of the Intensive Chemotherapy of Acute Leukaemia.- Treatment of Adenocarcinoma of the Ovary with Combined Immunotherapy and Chemotherapy.- Clinical and Experimental Studies on Immunochemotherapy Using OK-432, a New Streptococcal Preparation.- Phase I and Phase II Studies in the Treatment of Cancer Patients by Radiotherapy, Chemotherapy and Methanol Extraction Residue of an Anti-Tuberculosis Vaccine (MER).- Additional Therapy with Trenimon in Treatment of Carcinoma of the Uterine Cervix.- Interferences of Radiotherapy and Chemotherapy on the Binding of 3H-17?-oestradiol with Its Specific Receptors.- Mechanism of Antitumor Action of Hemolytic Streptococcal Preparation OK-432 (NSC-B116209) for Malignant Pleural or Peritoneal Effusion by Intrathoracal and Intraperitoneal Injection.- The Significance of Reduction Surgery in the Treatment of Advanced Cancer Patients.- Intermittent Long Term Polychemotherapy as an Adjuvant to Surgery of Bronchogenic Carcinoma.- Polychemotherapy for Advanced Lung Carcinoma: Clinical Results and Further Consequences.- Chemotherapy in Conservative Treatment of Lung Cancer Patients.- Effective Chemotherapy for Bronchial Carcinoma.- MUltidisciplinary Curative Assault on Disseminated Carcinoma of the Breast.- Potentiation of Drugs Using Sequential Chemotherapy Against Disseminated Breast, Bronchial, and Central Nervous System Solid Tumors.- Animal and Human Studies with Oral Mitomycin C(6): A Preliminary Report.- Chemohormonal Therapy of Breast Cancer - A Pilot Phase I-II Study.- The Results of Cleomycin Treatment in 90 Patients with Malignant Disease.- Cis-Platinum Diaminodichloride in the Treatment of Squamous Cell Carcinoma and Other Malignant Diseases.- Anhydro-Arabinosyl-Fluorocytosine HYdrochloride: A Phase I Study.- Ifosfamide in the Treatment of Lung Cancer and Metastases of Solid Malignant Tumours.- Preclinical and Phase-I Studies of Ifosfamide for Its Massive Dose Cumulation Schedule.- Clinical Pharmacological Studies with Formyl-Leurosin in Malignant Diseases.- Clinical Investigations with F-Leurosine.- Clinical Investigations of Dibramodulcitol in the Treatment of Malignant Diseases.- Oral Estracyt® (Estramustine phosphate) in the Treatment of Advanced Carcinoma o…